DAIICHI SANKYO, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: DS-1205c
Drug: Osimertinib

First Posted Date: 2017-08-21

Last Posted Date: 2022-01-19

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 13

Registration Number: NCT03255083

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳
Taipei Medical University Hospital, Taipei, Taiwan
🇨🇳
National Cheng-Kung University Hospital, Tainan, Taiwan

and more 4 locations

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: DS-8201a

First Posted Date: 2017-08-14

Last Posted Date: 2023-11-15

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 253

Registration Number: NCT03248492

Locations: 🇺🇸
The Regents of the University of California, Los Angeles, California, United States
🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 96 locations

Effect of Probenecid on Pexidartinib Pharmacokinetics

Phase 1

Completed

Conditions: Pharmacokinetics in Healthy Volunteers

Interventions: Drug: Pexidartinib
Drug: Probenecid

First Posted Date: 2017-05-03

Last Posted Date: 2017-05-03

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 16

Registration Number: NCT03138759

Locations: 🇺🇸
Worldwide Clinical Trials Early Phase Services, San Antonio, Texas, United States

DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

Phase 1

Terminated

Conditions: Leukemia, Myeloid, Acute
Leukemia, Lymphocytic, Acute

Interventions: Drug: DS-3201b

First Posted Date: 2017-04-12

Last Posted Date: 2024-01-31

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 28

Registration Number: NCT03110354

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations

Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas

Not Applicable

Active, not recruiting

Conditions: Glioma

Interventions: Drug: DS-1001b

First Posted Date: 2017-01-24

Last Posted Date: 2024-03-15

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 47

Registration Number: NCT03030066

Locations: 🇯🇵
National Cancer Center Hospital, Tokyo, Japan

Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

Phase 1

Terminated

Conditions: Colorectal Neoplasm

Interventions: Drug: DS-8273a + nivolumab

First Posted Date: 2016-12-13

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 4

Registration Number: NCT02991196

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas, United States
🇺🇸
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States

and more 1 locations

Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes

Not Applicable

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Edoxaban

First Posted Date: 2016-11-16

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 607

Registration Number: NCT02964949

Locations: 🇱🇹
Vilnius University Hospital Santariskiu Clinic Public Institution, Vilnius, Lithuania
🇵🇱
Synexus Polska Sp z o o Oddział we Wroclawiu, Wroclaw, Poland
🇷🇺
FSHI "MSU of MoIA of RF of Kemerovo Region", Kemerovo, Russian Federation

and more 227 locations

Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Edoxaban

First Posted Date: 2016-11-02

Last Posted Date: 2019-12-23

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 352

Registration Number: NCT02952599

Locations: 🇨🇳
Far Eastern Memorial Hospital, New Taipei City, Banciao District, Taiwan
🇨🇳
Taipei Veterans General Hospital, Taipei, Beitou District, Taiwan
🇨🇳
Chang Gung Memorial Hospital, KaoHsiung, Kaohsiung, Niaosong District, Taiwan

and more 16 locations

Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Edoxaban

First Posted Date: 2016-11-01

Last Posted Date: 2021-01-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 3008

Registration Number: NCT02951039

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Beitou District, Taiwan
🇰🇷
Soon Chun Hyang University Hospital Cheonan, Cheonan, Chungcheongnam-do, Korea, Republic of
🇰🇷
GangNeung Asan Hospital, Gangneung, Gangwon-do, Korea, Republic of

and more 44 locations

Edoxaban Management in Diagnostic and Therapeutic Procedures

Completed

Conditions: Atrial Fibrillation
Venous Thromboembolism

Interventions: Procedure: Edoxaban

First Posted Date: 2016-10-31

Last Posted Date: 2020-02-05

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 1197

Registration Number: NCT02950168

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy